Evaxion has initiated development of EVX-B4, a vaccine targeting Group A Streptococcus, using its AI-Immunology™ platform.
Quiver AI Summary
Evaxion A/S has announced the initiation of a new vaccine program, EVX-B4, targeting Group A Streptococcus (GAS), a pathogen responsible for a wide range of infections globally, including severe conditions like rheumatic heart disease and necrotizing fasciitis. Their AI-Immunology™ platform has demonstrated the ability to identify novel vaccine targets for GAS, highlighting the urgent need for preventive measures against this bacteria. The addition of EVX-B4 aligns with Evaxion's commitment to expanding their research and development pipeline, which includes other infectious diseases and cancer candidates, while also supporting their strategy for potential partnerships. As GAS infections continue to rise, the development of this vaccine represents both significant medical and commercial potential, demonstrating Evaxion's innovative approach to tackling infectious diseases.
Potential Positives
- Evaxion's AI-Immunology™ platform has demonstrated the ability to identify novel vaccine targets for combating Group A Streptococcus (GAS), indicating technological advancement in vaccine development.
- The introduction of the EVX-B4 vaccine program addresses a significant medical need for preventive measures against GAS infections, highlighting potential market demand and benefits to public health.
- The addition of EVX-B4 expands Evaxion’s R&D pipeline to five infectious disease candidates, enhancing the company’s portfolio and potential for strategic partnerships.
- The partnership strategy is reinforced as the comprehensive preclinical data package for EVX-B4 will facilitate discussions for out-licensing, potentially leading to new revenue streams.
Potential Negatives
- There is a significant dependency on partnerships for the success of the new vaccine candidate EVX-B4, indicating potential vulnerability if such partnerships do not materialize.
- The press release highlights the urgent need for a vaccine against Group A Streptococcus (GAS), which points to a limitation in current offerings and the company's need to address a serious health issue.
- The mention of potential risks related to financial condition, development work, and the need for additional capital suggests instability and uncertainty in the company's future.
FAQ
What is EVX-B4?
EVX-B4 is a new preventive vaccine program developed by Evaxion to combat Group A Streptococcus (GAS) infections.
How does AI-Immunology™ contribute to vaccine development?
AI-Immunology™ helps identify novel vaccine targets quickly and effectively, accelerating the development of candidates like EVX-B4.
What are the risks associated with Group A Streptococcus infections?
GAS infections can lead to severe complications, including rheumatic heart disease, sepsis, and necrotizing fasciitis.
Why is EVX-B4 important?
The urgent need for preventive measures against GAS highlights the significant medical and commercial potential of the EVX-B4 vaccine.
How many candidates are in Evaxion's R&D pipeline?
Evaxion's R&D pipeline now includes five infectious disease vaccine candidates and three for cancer.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EVAX Hedge Fund Activity
We have seen 1 institutional investors add shares of $EVAX stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MERCK & CO., INC. added 1,105,670 shares (+1019.5%) to their portfolio in Q1 2025, for an estimated $2,045,489
- ARMISTICE CAPITAL, LLC removed 30,092 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $55,670
- CITADEL ADVISORS LLC removed 14,825 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $62,665
- INVST, LLC removed 10,080 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $18,648
- CATALINA CAPITAL GROUP, LLC removed 6,973 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $12,900
- BLACKROCK, INC. removed 1,512 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $6,391
- BEACON CAPITAL MANAGEMENT, LLC removed 973 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,800
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Initial computational analysis demonstrated that Evaxion’s AI-Immunology™ platform can identify novel vaccine targets to combat
Group A
Streptococcus
(GAS)
New vaccine program is added to Evaxion’s pipeline under the name EVX-B4
Urgent need for preventive measures against GAS underscores the significant medical and commercial potential of EVX-B4
Addition of a novel infectious disease candidate to the pipeline is in line with Evaxion’s partnership strategy
COPENHAGEN, Denmark, June 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, initiates work to develop a new preventive vaccine against Group A
Streptococcus
(GAS), a bacteria causing hundreds of millions of infections globally each year. Infection carries the risk of several complications including life threatening conditions like rheumatic heart disease and necrotizing fasciitis (“flesh eating bacteria”) and less severe yet serious diseases like strep throat and scarlet fever.
The new vaccine program, named EVX-B4, has been added to Evaxion’s research & development (R&D) pipeline of cancer and infectious disease vaccine candidates. Initial computational analysis demonstrated that AI-Immunology™ can identify novel vaccine targets to combat GAS, which could pave the way for a new approach to fight the bacteria. Deploying AI-Immunology™ allows for fast and effective target discovery, design and validation, accelerating preclinical development of EVX-B4. This work will create a comprehensive preclinical data package to facilitate partnership discussions.
“We are excited to add EVX-B4 to our R&D pipeline following an extensive evaluation of numerous bacterial pathogens causing severe medical complications, and for which no preventive vaccine exists. With guidance from a panel of world-renowned experts, we prioritized GAS as a key target where our AI-Immunology™ platform could provide substantial benefit. The urgent need for options to prevent GAS infections is huge, underscoring the significant medical and commercial potential of EVX-B4 as well as multiple partnering options,” says Birgitte Rønø, CSO of Evaxion.
Adding EVX-B4 to the pipeline achieves another of Evaxion’s milestones for 2025. Evaxion’s R&D pipeline now comprises five specified vaccine candidates for infectious diseases and three for cancer. The build-up of the pipeline supports Evaxion’s partnership strategy as we increase the number of assets for out-licensing.
About GAS
Group A
Streptococcus
(GAS) can cause a wide range of conditions ranging from life-threatening to mild depending on the severity of infection. Invasive GAS infections can cause diseases like sepsis, toxic shock, rheumatic heart disease and necrotizing fasciitis (“flesh eating bacteria”), all of which can be fatal if not treated immediately.
The U.S. rates of invasive GAS disease began increasing in 2014. The increase was largest among adults aged 18 through 64 years, but the rate also increased among older adults. Annually, 20,000 to 27,000 cases and 1,800 to 2,400 deaths are estimated in the US.
Worldwide, rheumatic heart disease remains a significant cause of cardiovascular disease and death. The World Health Organization estimates 470,000 new cases of acute rheumatic fever and 282,000 new cases of rheumatic heart disease each year. In 2015, there was an estimated 33.4 million cases of rheumatic heart disease. In addition, over 300,000 people die each year from rheumatic heart disease or its complications.
The number of non-invasive GAS infections, which can cause diseases like strep throat (pharyngitis), scarlet fever and impetigo, are estimated to be much higher. The World Health Organization estimates that each year over 100 million children worldwide have impetigo and over 600 million have pharyngitis due to GAS. (Source:
The US Centers for Disease Control and Prevention
).
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About Evaxion
Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please
visit our website
.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at
www.sec.gov
. We do not assume any obligation to update any forward-looking statements except as required by law.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
